Clinical trial Recruiting at 2 sites Observational Ages 18 and up

Using AI to Diagnose Solid Pancreatic Lesions

Official title: 内镜超声穿刺胰腺实性占位细胞涂片快速染色后全玻片扫描及人工智能诊断:一项前瞻性、多中心研究

Run by Ruijin Hospital · NCT06824909 · Data updated 2026-11-12

This study is testing a new AI system to see if it can help doctors better and faster diagnose solid pancreatic lesions during an ultrasound procedure.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1500 (estimated)
SponsorRuijin Hospital
Academic / other
Locations2 sites (Shanghai, Shanghai Municipality and 1 other locations)
StatusRecruiting
StartedDecember 31, 2024
Main results expectedMay 31, 2027
Study endsJune 30, 2027
Registry record updatedFebruary 13, 2025
Trial IDNCT06824909 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and above with a diagnosis or suspicion of solid pancreatic lesions based on imaging studies.

Probably not a fit

Patients with pancreatic cystic lesions or those unable to provide informed consent will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of a self-developed artificial intelligence diagnostic system, known as the ROSE-AI system, in diagnosing solid pancreatic lesions through endoscopic ultrasound-guided fine-needle aspiration. The study will utilize optical imaging technology to capture images of stained cytological smears and compare the AI-generated diagnoses with actual pathological results. By focusing on differentiating various pancreatic diseases, including pancreatic ductal adenocarcinoma and neuroendocrine tumors, the study seeks to improve diagnostic accuracy and speed.

Why it matters

Potential benefit: If successful, this study could lead to faster and more accurate diagnoses of pancreatic diseases, improving patient outcomes.

How similar studies have gone: Other studies have shown promise in using AI for diagnostic purposes, but this specific approach is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* A dated and signed informed consent form A commitment to abide by the research procedures and cooperate throughout the entire study Subjects aged 18 and above, regardless of gender Diagnosis or suspicion of a solid pancreatic space-occupying lesion based on imaging studies (B-mode ultrasound, CT, or MRI)

Exclusion Criteria:

* Unable or refusing to sign the informed consent form Unable to suspend anticoagulation/antiplatelet therapy Pregnant or lactating Having a mental illness or other medical conditions that are unsuitable for undergoing FNA/B biopsy Presence of coagulation disorders (PLT \< 50 × 10\^3/μl, INR \> 1.5) Pancreatic cystic lesions Non-diagnostic EUS-FNA/B specimens Having less than 8 microscopic fields of interest (ROI) in the digital pathology images of the entire Diff-Quik smear slide

Where it's running

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting
  • Department of Gastroenterolog, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.